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A B ST R AC T  
 
Ureteral obstruction following bulking agent injection for treatment of vesicoureteral reflux is rare. 
Herein we report a case of acute bilateral ureteral obstruction following bilateral 
Dextranomer/hyaluronic acid polymer injection. The obstruction which manifested hours following 
the injection, was treated with prompt insertion of bilateral ureteral stents. The stents were removed 
4 weeks later with complete resolution of the obstruction. We believe that ureteral stenting is an 
excellent solution for acute ureteral obstruction following Dextranomer/hyaluronic acid polymer 
injection. 
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Introduction 
Endoscopic correction of low grade 
vesicoureteral (VUR) with bulking agents has 
solely replaced the use of open ureteral re-
implantation as first line treatment [1]. The 
success rate of Dextranomer/hyaluronic acid 
polymer (Dx/Ha) injection is excellent and 
reported to be as high as 84%-93% for overall 
treatment [2-4]. 
Complications are usually mild and include 
flank pain, postoperative cystitis, rarely 
pyelonephritis and de-novo contralateral VUR. 
Ureteral obstruction has been reported to be 
extremely rare with a reported incidence of 0.7-
2.1% [5,6]. Obstruction may present in the 
acute or late setting. We present the first 
reported case of acute bilateral ureteral 
obstruction following bilateral Dx/Ha injection 
in a 6 year old girl.  
 
Case report 
The patient was first referred to our clinic at 
32-months of age for evaluation of recurrent 
urinary tract infection (UTI). A voiding 
cystourethrogram (VCUG) revealed a bilateral 
grade 2 VUR. Dimercaptosuccinic acid 
(DMSA) scan showed differential function of 
65% & 35% on the right and left kidneys, 
respectively with scars on the upper and lower 
left poles. She was scheduled for bilateral 
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bulking agent injection for which her parents 
refused and disappeared from follow-up.  
During the next 3 years she continued to 
experience breakthrough UTI's some of which 
were febrile (under prophylactic cephlaxin 
treatment). A repeated DMSA scan 4 years 
later reveals now a worsening left kidney 
function (differential function of 80% to the 
right & 20% to the left) with a new right upper 
pole scar. At that time she was again referred 
to our clinic and a bilateral Dx/Ha injection 
was carried out with 1 cc and 0.8cc injected to 
the left and right orifices, respectively, using 
the hydrodistention implantation technique 
(HIT). Intraoperative cystoscopic results were 
good and a urethral catheter was left 
indwelling. The procedure was otherwise 
uneventful. In the hours following the 
procedure the patient was anuric despite 
adequate hydration and complained of bilateral 
flank pain. Post procedure serum creatinine 
rose to 2.3 mg/dl (from a baseline of 0.5 
mg/dl). Bedside sonography revealed bilateral 
hydronephrosis. Bilateral indwelling ureteric 
stents were placed the following morning 
under general anesthesia with subsequent 
normal urine output and a prompt decline in 
serum creatinine to baseline. Four weeks later 
the stents were removed uneventfully. Eight 
weeks after the initial procedure 
ultrasonography revealed no hydronephrosis 
and good bilateral ureteral jets [Fig. 1].  
 
Fig. 1. Bilateral ureteral jets on sonography 8 
weeks post injection. 
On 3 months follow-up the patient didn't 
develop breakthrough UTI's. A follow up 
VCUG is scheduled.   
 
Discussion 
The use of Dx/Ha injection for vesicoureteral 
reflux is well established and is currently the 
preferred agent used in most centers 
worldwide [7]. Post procedure follow up 
usually consists of ultrasound and VCUG [8]. 
Ureteral obstruction following Dx/Ha injection 
is uncommon. Snodgrass reported the first case 
of obstruction following Dx/Ha injection in 
2004 [9]. Vandersteen et al reported in their 
multicenter study of 745 patients with 1155 
ureters injected with Dx/Ha (up to 1CC), a rate 
0.7% postoperative ureteral obstruction [5]. 
All patients were treated with indwelling 
ureteral stent placement, with resolution of 
symptoms after placement and no recurrence 
upon removal in all patients. 4 of the 5 patients 
reported developed an acute obstruction. In 
their report only 1 (14%) obstructed ureter had 
a previously demonstrated grade 2 reflux while 
the others had higher grades. 80% of the 
children reported had reflux secondary to 
myelomeningocele or dysfunctional voiding. 
Baybikov recently reported an unpublished 
retrospective multicenter analysis of 4898 
ureters injected with different bulking agents 
including Dx/Ha with a 0.7% obstruction rate. 
Of the 33 ureters obstructed, 12 occurred in the 
acute setting (first 24 hours), of them one was 
anuric with a single kidney. Ureteral stenting 
was the initial management in 6 of the acutely 
obstructed patients. Of these, 5 were 
successfully treated with stenting alone. 
Stenting in the late obstruction group was 
unsuccessful in all ureters stented [10]. It 
should be noted that others reported a slightly 
higher incidence of obstruction than 0.7% [6].  
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Most cases concerning ureteral obstruction 
have been reported in the late period following 
injection rather than the acute setting. The only 
reported case of bilateral obstruction following 
Dx/Ha injection was reported by Nseyo et al. 
but this occurred 11 months after the injection 
[11]. 
As others previously proposed, we believe that 
the most reasonable etiology for acute ureteral 
obstruction following Dx/Ha injection is 
transient orifice edema secondary to injection 
related trauma combined with the Dx/Ha 
mound. This is most reasonable given the 
standard and acceptable low volume of Dx/Ha 
injected.     
As previously reported [5], visualization of the 
orifice in the acute setting is difficult when 
attempting stent insertion but directing the 
guide wire to the apex of the newly formed 
mound made catheterization of the orifice 
straightforward. We recommend that the 
injecting urologist be present upon stent 
insertion to better direct stent placement, 
especially when preformed in the acute setting.  
Ureteral obstruction following Dx/Ha injection 
is a serious though rare complication requiring 
urgent attention and treatment. Insertion of an 
indwelling ureteral stent is an excellent 
management option in the acute setting with 
good results.    
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